Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:
Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:
Active, not recruiting · NCT03875573 · Registry updated 2026-10-07Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer: | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, luminal B breast carcinoma, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-10-07 | NCT03875573 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AstraZeneca | 806 |
| Institut Curie | 48 |
| Jules Bordet Institute | 39 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Centre Georges François Leclerc | Dijon | France | 42 |
| CHU UCL Namur Sainte-Elisabeth | Namur | Belgium | 2 |
| Cliniques Universitaires Saint-Luc | Brussels | Belgium | 147 |
| GZA - Ziekenhuizen (Campus St. Augustinus) | Wilrijk | Belgium | 1 |
| Institut Curie | Paris | France | 51 |
| Institut Jules Bordet | Brussels | Belgium | 18 |
| Universitaire Ziekenhuizen | Leuven | Belgium | 1 |